A patient’s perspective: Life in remission after Hodgkin lymphoma

Carol Jarvis, a professional musician who was diagnosed with Hodgkin lymphoma in 2004, talks about living in remission with the disease. Carol shares her insights into her journey from diagnosis to remission as part of her treatment journey where following an ASCT she received ADCETRIS (brentuximab vedotin) and subsequent other therapies.

This interview reflects Carol’s personal experience of treatment with ADCETRIS, where she received ADCETRIS following an ASCT. She talks through the side effects she experienced, and how it felt to be told she was in remission after her fourth cycle of treatment with ADCETRIS. Carol offers her perspective and a message on never giving up hope.

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 

1. following autologous stem cell transplant (ASCT), or 
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 

For additional indications, please refer to the ADCETRIS SmPC.¹ 

If you would like to discuss this content with a Takeda representative, please click here. 

This interview reflects the personal experience of Carol, and may not represent the experiences of all patients, as individual outcomes and responses to treatment can vary.

ASCT, autologous stem cell transplant; SmPC, Summary of Product Characteristics.              
1. ADCETRIS® Summary of Product Characteristics.